Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

[Intranasal co-administration of recombinant streptococcus group B polypeptides and influenza deltaNS1 vaccine].

Shurygina AP, Leont'eva GF, Grabovskaia KB, Gupalova TV, Koroleva IV, Kramskaia TA, Kiselev OI, Egorov AIu, Suvorov AN.

Vopr Virusol. 2013 May-Jun;58(3):28-31. Russian.

PMID:
24006630
2.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

3.

Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination.

Ikeda K, Ainai A, Hasegawa H.

Vaccine. 2015 Nov 9;33(45):6066-9. doi: 10.1016/j.vaccine.2015.09.072. Epub 2015 Oct 1.

PMID:
26432916
4.

[Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].

Stepanova LA, Kovaleva AA, Potapchuk MV, Korotkov AV, Kupriianov VV, Blokhina EA, Kotliarov RIu, Tsybalova LM.

Vopr Virusol. 2013 May-Jun;58(3):21-5. Russian.

PMID:
24006628
5.

Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.

Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.

J Virol. 2015 Jul;89(14):7224-34. doi: 10.1128/JVI.00585-15. Epub 2015 May 6.

6.

Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.

Klingbeil K, Lange E, Blohm U, Teifke JP, Mettenleiter TC, Fuchs W.

Virus Res. 2015 Mar 2;199:20-30. doi: 10.1016/j.virusres.2015.01.009. Epub 2015 Jan 17.

PMID:
25599604
7.

Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.

Yang P, Duan Y, Zhang P, Li Z, Wang C, Dong M, Tang C, Xing L, Gu H, Zhao Z, Liu X, Zhang S, Wang X.

PLoS One. 2012;7(1):e30252. doi: 10.1371/journal.pone.0030252. Epub 2012 Jan 18.

8.

Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Ryder AB, Nachbagauer R, Buonocore L, Palese P, Krammer F, Rose JK.

J Virol. 2015 Dec 16;90(5):2544-50. doi: 10.1128/JVI.02598-15.

9.

Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.

Chowdhury MY, Seo SK, Moon HJ, Talactac MR, Kim JH, Park ME, Son HY, Lee JS, Kim CJ.

Virol J. 2014 Feb 6;11:21. doi: 10.1186/1743-422X-11-21.

10.

Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice.

Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo CY, Perez DR, Ye J, Tompkins SM, Epstein SL.

PLoS One. 2011;6(7):e21937. doi: 10.1371/journal.pone.0021937. Epub 2011 Jul 15.

11.

Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.

de Haan A, Haijema BJ, Voorn P, Meijerhof T, van Roosmalen ML, Leenhouts K.

Vaccine. 2012 Jul 6;30(32):4884-91. doi: 10.1016/j.vaccine.2012.04.032. Epub 2012 Apr 23.

PMID:
22537989
12.

Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Wu R, Zhang H, Zheng M, Wang H, Chen Z.

Arch Virol. 2010 Apr;155(4):535-44. doi: 10.1007/s00705-010-0621-4. Epub 2010 Feb 27.

PMID:
20195654
14.

Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice.

Meng S, Liu Z, Xu L, Li L, Mei S, Bao L, Deng W, Li L, Lei R, Xie L, Qin C, Zhang L.

PLoS One. 2011;6(5):e19863. doi: 10.1371/journal.pone.0019863. Epub 2011 May 20.

15.

Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA.

Li J, Arévalo MT, Diaz-Arévalo D, Chen Y, Choi JG, Zeng M.

J Control Release. 2015 Jun 10;207:70-6. doi: 10.1016/j.jconrel.2015.04.001. Epub 2015 Apr 7.

16.

Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.

Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan AC, Mercuri F, Rockman S, Chen W, Turner SJ, Doherty PC, Kelso A, Brown LE, Jackson DC.

MBio. 2015 Oct 27;6(6):e01024-15. doi: 10.1128/mBio.01024-15.

17.

The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.

Lee JS, Chowdhury MY, Moon HJ, Choi YK, Talactac MR, Kim JH, Park ME, Son HY, Shin KS, Kim CJ.

J Virol Methods. 2013 Dec;194(1-2):280-8. doi: 10.1016/j.jviromet.2013.08.022. Epub 2013 Sep 1.

PMID:
24004822
18.

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.

Sui Z, Chen Q, Fang F, Zheng M, Chen Z.

Vaccine. 2010 Nov 10;28(48):7690-8. doi: 10.1016/j.vaccine.2010.09.019. Epub 2010 Sep 24.

PMID:
20870054
19.

Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.

Ichinohe T, Ainai A, Nakamura T, Akiyama Y, Maeyama J, Odagiri T, Tashiro M, Takahashi H, Sawa H, Tamura S, Chiba J, Kurata T, Sata T, Hasegawa H.

J Med Virol. 2010 Jan;82(1):128-37. doi: 10.1002/jmv.21670.

PMID:
19950232
20.

[Experimental evaluation of recombinant polypeptides as Streptococcus Group B vaccine].

Leont'eva GF, Suvorov AN, Meringova LF, Grabovskaia KB, Ustinovich IA, Totolian AA.

Zh Mikrobiol Epidemiol Immunobiol. 2005 Mar-Apr;(2):35-40. Russian.

PMID:
15881936

Supplemental Content

Support Center